{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:29:48Z","timestamp":1792290588700,"version":"4.4.0"},"reference-count":44,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Biopharm &amp; Drug Disp"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Encorafenib is used to treat melanoma and colorectal tumors. Depression and gastric ulcer conditions can impact various physiological processes, including drug metabolism and pharmacokinetics. This study investigated the effect of a rat model of depression and gastric ulcers on the pharmacokinetics (PK) of encorafenib using the developed LC\u2010QqQ\u2010MS method. The chronic unpredictable mild stress (CUMS) model of depression and the indomethacin\u2010induced gastric ulcer model were utilized to investigate the effect of depression and gastric ulcers on the pharmacokinetics of orally administered encorafenib. The focus was on parameters such as maximum plasma concentration (\n                    <jats:italic>C<\/jats:italic>\n                    <jats:sub>max<\/jats:sub>\n                    ), elimination half\u2010life (\n                    <jats:italic>t<\/jats:italic>\n                    <jats:sub>1\/2<\/jats:sub>\n                    ), mean residence time (MRT), volume of distribution (V\n                    <jats:sub>d<\/jats:sub>\n                    ), area under the curve (AUC), and apparent clearance (CL\/F). Rats with depression exhibited a significant increase in maximum plasma concentration (\n                    <jats:italic>C<\/jats:italic>\n                    <jats:sub>max<\/jats:sub>\n                    ). In contrast, depression led to decreased\n                    <jats:italic>t<\/jats:italic>\n                    <jats:sub>1\/2<\/jats:sub>\n                    and MRT, implying alterations in the drug's absorption and clearance. On the one hand, rats with gastric ulcers displayed a significant decrease in\n                    <jats:italic>C<\/jats:italic>\n                    <jats:sub>max<\/jats:sub>\n                    , coupled with an extended time to reach maximum plasma concentration (\n                    <jats:italic>T<\/jats:italic>\n                    <jats:sub>max<\/jats:sub>\n                    ), prolonged\n                    <jats:italic>t<\/jats:italic>\n                    <jats:sub>1\/2<\/jats:sub>\n                    , MRT, and increased volume of distribution (Vd) of encorafenib. This preclinical study demonstrates that depression and gastric ulcers significantly impact the pharmacokinetics of encorafenib. These findings emphasize the importance of considering these disease conditions when designing encorafenib dosing regimens for optimal therapeutic outcomes in cancer patients.\n                  <\/jats:p>","DOI":"10.1002\/bdd.70006","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T12:07:46Z","timestamp":1744200466000},"page":"67-81","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Influence of a Rat Model of Depression and Gastric Ulcer on the Pharmacokinetics of Encorafenib"],"prefix":"10.1002","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0449-4282","authenticated-orcid":false,"given":"Siva Nageswara Rao","family":"Gajula","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Analysis National Institute of Pharmaceutical Education and Research (NIPER)  Hyderabad India"},{"name":"Department of Pharmaceutical Analysis GITAM School of Pharmacy GITAM (Deemed to be University)  Visakhapatnam India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Munjal","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis National Institute of Pharmaceutical Education and Research (NIPER)  Hyderabad India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasikala","family":"Talari","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis National Institute of Pharmaceutical Education and Research (NIPER)  Hyderabad India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziaur","family":"Rahman","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology National Institute of Pharmaceutical Education and Research (NIPER)  Hyderabad India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj P.","family":"Dandekar","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology National Institute of Pharmaceutical Education and Research (NIPER)  Hyderabad India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Sonti","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis National Institute of Pharmaceutical Education and Research (NIPER)  Hyderabad India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/jssc.70099"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010021\u201001501\u20105"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31943"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318\u2010011\u20100077\u20102"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2018.12.002"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijpsym.ijpsym_512_17"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2023.106550"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.2c00143"},{"key":"e_1_2_8_10_1","volume-title":"SPEC\u2013Medicines for Cancer: Mechanism of Action and Clinical Pharmacology of Chemo, Hormonal, Targeted, and Immunotherapies, 12\u2010Month Access, eBook: Mechanism of Action and Clinical Pharmacology of Chemo, Hormonal, Targeted, and Immunotherapies","author":"De S. K.","year":"2023"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201016\u20102923"},{"issue":"4","key":"e_1_2_8_12_1","first-page":"427","article-title":"Pharmacokinetics of 5\u2010Fluorouracil and Cyclophosphamide in Depression Rats","volume":"16","author":"Duan J.","year":"2012","journal-title":"European Review for Medical and Pharmacological Sciences"},{"key":"e_1_2_8_13_1","unstructured":"EMA. (2011).EMA. Guideline on Bioanalytical Method Validation."},{"key":"e_1_2_8_14_1","volume-title":"Braftovi\u2122 (Encorafenib) Capsules","author":"FDA U.","year":"2018"},{"key":"e_1_2_8_15_1","unstructured":"Food U. andD.Administration.2001.Guidance for Industry. Bioanalytical Method Validation.http:\/\/www.fda.gov\/cder\/guidance\/4252fnl.htm."},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/sscp.202400163"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/rpsppr\/rqad017"},{"issue":"2","key":"e_1_2_8_18_1","first-page":"1","article-title":"Chronic Stress and the HPA Axis","volume":"9","author":"Guilliams T. G.","year":"2010","journal-title":"Standard"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.5152\/eurasianjmed.2018.0010"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010020\u201070312\u20107"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/cco.0000000000000426"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2013.816283"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.737716"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102036.2008.03906.x"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000007828"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2016.02.045"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114331"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/biology11111621"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.10.142"},{"issue":"35","key":"e_1_2_8_30_1","first-page":"171","article-title":"Relationship Between Mindfulness, Coping and Perceived Stress With Quality of Life in Cancer Patient","volume":"9","author":"Nejad Ahmadi N.","year":"2014","journal-title":"Journal of Modern Psychological Researches"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432\u2010022\u201004187\u20108"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/fbp.0000000000000564"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/2048731"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/1534735418756192"},{"issue":"7","key":"e_1_2_8_35_1","first-page":"1005","article-title":"Peptic Ulcer Disease","volume":"76","author":"Ramakrishnan K.","year":"2007","journal-title":"American Family Physician"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c01460"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio\u20102023\u20100030"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio\u20102023\u20100030"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2023.105483"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010018\u20100963\u2010x"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i18.2147"},{"key":"e_1_2_8_42_1","volume-title":"StatPearls [Internet]","author":"Thau L.","year":"2021"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2021.05.010"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3418975"},{"issue":"4","key":"e_1_2_8_45_1","first-page":"655","article-title":"Selective COX\u20102 Inhibitors: A Review of Their Structure\u2010Activity Relationships","volume":"10","author":"Zarghi A.","year":"2011","journal-title":"Iranian Journal of Pharmaceutical Research: IJPR"}],"container-title":["Biopharmaceutics &amp; Drug Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdd.70006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T12:07:34Z","timestamp":1767874054000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/bdd.70006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1002\/bdd.70006"],"URL":"https:\/\/doi.org\/10.1002\/bdd.70006","archive":["Portico"],"relation":{},"ISSN":["0142-2782","1099-081X"],"issn-type":[{"value":"0142-2782","type":"print"},{"value":"1099-081X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2025-03-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}